The Harvard spinout had raised $10m in seed funding from investors including Arch Venture Partners, but disappointing animal studies led the company to be wound down.

Ally Therapeutics, a US-based gene therapy developer spun out of Harvard University, has halted operations, Endpoints News reported yesterday.
The spinout shut down “earlier this year” following disappointing results in animal trials.
Founded in 2018, Ally Therapeutics was looking to prevent an immune response to gene therapies. It was based on research from Ying Kai Chan, a postdoctoral researcher in the lab of George Church, himself a prolific entrepreneur who has co-founded dozens of spinouts.
Arch Venture…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in